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Abstract
Background: Mesenchymal stem cells (MSCs) transplantation has become a promising therapeutic choice for
musculoskeletal injuries. Joint-related disorders are highly prevalent in horses. Therefore, these animals are
considered as suitable models for testing MSC-based therapies for these diseases. The aim of this study was to
investigate the clinical and inflammatory responses to intra-articular single and repeat dose administration of
autologous or of pooled allogeneic MSCs in healthy equine healthy joints. Six horses were intra-articularly injected
with a single autologous dose of bone marrow derived MSCs (BM-MSCs) and two separate doses of allogeneic
BM-MSCs pooled from several donors. All contralateral joints were injected with Lactated Ringer’s Solution (LRS) as
the control vehicle. Signs of synovitis and lameness were evaluated at days 0, 1, 2, 3, 5 and 10 after injection. Total
protein (TP), white blood cell count (WBC) and neutrophil count (NC) in synovial fluid were also measured at the
same time-points.
Results: A mild synovial effusion without associated lameness was observed after all BM-MSCs injections. The
second allogeneic injection caused the lowest signs of synovitis. Local temperature slightly increased after all
BM-MSCs treatments compared to the controls. TP, WBC and NC in synovial fluids also increased during days 1 to 5
after all BM-MSCs injections. Both, clinical and synovial parameters were progressively normalized and by day 10
post-inoculation appeared indistinguishable from controls.
Conclusions: Intra-articular administration of an allogeneic pool of BM-MSCs represents a safe therapeutic strategy
to enhance MSCs availability. Importantly, the absence of hypersensitivity response to the second allogeneic
BM-MSCs injection validates the use of repeat dose treatments to potentiate the therapeutic benefit of these cells.
These results notably contribute to the development of stem cell based therapies for equine and human joint
diseases.
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Background
Osteoarthritis (OA) is an irreversible degenerative dis-
ease characterized by articular cartilage loss and syn-
ovial inflammation. Current OA therapeutic strategies
are focused on reducing pain, physical disability and
handicap, and try to limit structural deterioration in
affected joints [1, 2].
Cell therapy using stem cells has become a large field
of research focusing on the development of effective
treatments for this disease [3]. Mesenchymal stem cells
(MSCs) are studied as a possible tool for cell therapy not
only by their “stem” properties and differentiation poten-
tial but also by their trophic and immunomodulatory
properties [4, 5]. Horses commonly suffer from OA and
osteochondrosis, being diseases of great concern for
equine clinicians [6]. In addition, horses are considered
the most appropriate animal model for testing the clin-
ical effects of MSC-based therapies for humans joint
injuries [7].
While both autologous and allogeneic MSCs therapies
have been used for the treatment of several diseases [8],
the use of allogeneic MSCs has gained relevance due to
their shorter ex vivo expansion time [9] and the possibil-
ity to be selected according to their characteristics to
optimize the treatment (higher immunomodulatory cap-
acity, rate of growth in culture, etc).
The administration of a single dose and repeat doses
of allogeneic-derived MSCs obtained from one donor
has been tested in equine under different conditions
[10–12]. Although it has been demonstrated that repeat
injections of MSCs can enhance the benefit of these cells
in different pathology models and administration routes
[13, 14], it remains unclear if allogeneic MSCs can pro-
voke an immunoresponse [15, 16]. Using single-donor
allogeneic MSCs has some constraints, such as the
donor selection or the number of cells obtained under
culture conditions. Therefore, the use of MSCs pooled
from several donors could be advantageous.
To our knowledge, safety of repeat intra-articular ad-
ministrations of allogeneic bone-marrow derived MSCs
(BM-MSCs) pooled from several donors has not been
yet studied in horses. Neither their safety profile can be
extrapolated from allogeneic-single administration of
one-donor MSCs [10, 17]. Hence, in this work we evalu-
ate the clinical and inflammatory response to the admin-
istration of autologous and repeat doses of allogeneic
BM-MSCs pooled from several donors in tarso-crural
and radio-carpal equine healthy joints.
Results
MSC isolation, differentiation and characterization
Approximately 80 x 106 BM-MSCs in third passage were
successfully obtained from the bone marrow aspirate of
each horse. Gene expression of the surface marker
antigens CD90, CD105, CD73 and CD166 were positive,
whereas no mRNA was detected for haematopoietic
markers CD45 and CD34. Specific dyes confirmed the
ability of the cells to differentiate into osteogenic, adipo-
genic and chondrogenic lineages after induction with
corresponding media. Characterization data are pre-
sented in Fig. 1 and Additional file 1. Viability and pro-
liferation of cryopreserved cells was confirmed by the
maintenance of similar cell doubling time (DT) after
thawing. MSC gene expression of MHC-I and MHC-II is
showed in Fig. 1. Moderate expression of MHC-I and
low expression of MHC-II were reported, according to
previous studies [18].
Clinical assessment
No visual evidence of synovitis was observed in the con-
trol joints in any of three injections. Some articular dis-
tension was detected on treated joints in all
experiments. The visual exam showed a marked disten-
sion only in two joints injected with autologous MSCs
(Injection 1). Mild synovial effusion after the first allo-
geneic pool of MSCs administration (Injection 2) was
observed, whereas the allogeneic reinjection (Injection
3) provoked only a slight distention. In addition, a slight
increase in local temperature was observed (Fig. 2), ran-
ging from 0.5 to 3 °C after Injection 1 in the treated
joints compared with contralateral joints injected with
Lactated Ringer’s Solution (LRS) as control. In Injec-
tions 2 and 3, the average temperature increase in
treated joints respect their controls was less than 1 °C.
Fig. 1 Mean ± standard error (S.E.) of relative mRNA expression
(y axis) of 6 antigens surface markers (light grey) and 2 major
histocompatibility complex molecules (dark grey) (x axis) for BM-MSCs
(n= 6) examined by RT-qPCR. The BM-MSC used in this study were
positive for CD90, CD105, CD73, CD166 and MHC-I and negative for
CD34 and CD45. MHC-II was expressed at low level
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In all cases, the normal values were restored between 3
and 10 days and differences were not statistically signifi-
cant at any time for any Injection.
Throughout the study none of the animals showed
lameness in trot, except one horse after Injection 1. The
lameness gradually decreased over time and absent at
day 10 (Additional file 2). Ultrasonography findings were
compatible with transient slight synovitis in treated
animals receiving Injections 1, 2 and 3. Ultrasonographic
signs of synovitis disappears by10 days post-inoculation.
Re-injected joints (Injection 3) showed the lowest signs
of synovitis (Fig. 3).
Fig. 2 Mean ± standard deviation of difference in local temperature and synovial fluid parameters in Injections 1, 2 and 3. Mean ± standard
deviation (SD) of difference in local temperature and synovial fluid parameters analyzed for autologous (Injection 1), allogeneic (Injection 2) and
repeat allogeneic (Injection 3) mesenchymal stem cell (MSC) injected joints compared to controls. a Difference in local temperature (°C) between
MSC injected joints (TR.) and control (CTRL.) joints (local temperature in MSC injected joints – local temperature in control joints) at each time
point for Injection 1 (A1), Injection 2 (A2) and Injection 3 (A3). b Total protein concentration (g/dL) at each time point for Injection 1 (B1),
Injection 2 (B2) and Injection 3 (B3). c White blood cell count (cells/μl) at each time point for Injection 1 (C1), Injection 2 (C2) and Injection 3 (C3).
d Neutrophil count (cells/μl) at each time point for Injection 1 (D1), Injection 2 (D2) and Injection 3 (D3). Asterisk symbol (*) indicates statistically
significant difference (p <0.05) between mean ± SD in control and MSC treated joints at each time point. Controls are represented as dotted lines
and treated as solid lines
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Assessment of synovial fluids
TP, WBC and NC values at each time-point are represented
in Fig. 2 and Additional file 3 .
Total protein (TP)
A non-significant transient increase of TP values (<2gr/dL)
was observed in control joints injected with LRS.
Significant differences in TP values between treated
and control joints were detected post-injection on days
1 and 2 (Injection 1), days 2 and 5 (Injection 2) and
days 1, 2, 3 and 5 (Injection 3). The largest TP increase
was detected 24 h post-Injection 3. In all cases the TP
progressively decreased reaching normal-healthy values
(<2gr/dL) on the 10th day post-inoculation.
White blood cells count (WBC)
A moderate rise in WBC was observed in all control
joints (Additional file 3). WBC counts increased in all
treated joints. The increase was statistically significant
after inoculation on days 1, 2 and 5 after Injections 1
and 3. No significant differences in WBC values were
found after Injection 2 at any time point. WBC values
diminished to normal reference ones in all cases by the
10th day.
Neutrophil count (NC)
Control joints showed a slight increase in NC after the
three Injections (Additional file 3). The NC increase in
treated joints was evident on day 1 after the three Injec-
tions, being statistically significant for Injections 1 and 3.
This NC increment suddenly decreased at 48 h post-
injection and remained low until reaching normal refer-
ence range on day 10.
Discussion
In our work, we have evaluated the clinical and inflam-
matory responses of healthy equine joints after intra-
articular injections of autologous and allogeneic single
and repeat pool of BM-MSCs. BM-MSCs were used due
to their regenerative performance and its ability to inte-
grate into the soft tissue joint [19, 20] as well as their
anti-inflammatory and immunomodulatory properties
[4]. Equine species was selected due to its availability as
human joint disease model [21] and its own relevance in
veterinary medicine [22]. Healthy joints were chosen to
approach articular immunoresponse to repeat allogeneic
injections of BM-MSCs. Behavior and properties of
MSCs, such their migratory pattern [23] or the safety of
therapeutic strategies based on MSCs [24, 25], are usually
prior studied in healthy animals. The conditions in healthy
and inflamed joints are different (i.e. vascularization,
leukocyte traffic), so the response of healthy joints to
repeat allogeneic MSCs cannot be directly extrapolated.
Despite these differences, performing a preliminary study
in healthy joints seems mandatory since if a negative
response in normal joints would have been observed, this
Fig. 3 Longitudinal ultrasound images of representative MSC-injected tarso-crural and radio-carpal joints after Injections 1, 2 and 3. The transducer
was longitudinally placed on the lateral plantar pouch of the tibiotarsal joint or in the dorsal aspect of the carpus, parallel and medial to the
extensor carpi radialis tendon, at the level of the radio-carpal joint. Images are recorded previous to the IA injection of BM-MSCs (T0), and
1 day (T1) and 10 days (T10) after BM-MSC injection. Distance between the bone surface and the skin was measured in two points at every
time. Slight distension and effusion was observed 1 day after all BM-MSC injection, which was normalized by the 10th day. Ta = talus, Ti = tibia,
R = radius, RC = radio-carpal bone, * = synovial fluid (effusion) in tarso-crural or radio-carpal joint, white arrow indicates the bone surface
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would discourage the use of repeat allogeneic doses of
MSCs in altered joints.
There are a few of very recent studies comparing the
immune response to autologous and allogeneic mesen-
chymal stem cells intra-articular injections in horses,
both in normal joints [10, 26, 27] and inflamed joints
[28]. However, none of these studies assess the use of a
pool of allogeneic donors and the re-inoculation of joints
with a second dose of cells. The use of repeat doses of
MSCs could be very important in order to potentiate the
MSC therapeutic effect, as it has been demonstrated in
other species and diseases [13, 14]. Using a pool of allo-
geneic MSC donors is also interesting in order to avoid
individual variations and limited number of MSCs in
some cases.
The BM-MSCs showed a normal growth pattern, with
a proliferation rate and viability similar to other studies
[29, 30]. After cryopreservation, the cells showed a
normal growth pattern indicating no effect on growth.
According to previous reports [31], equine BM-MSCs
displayed similar gene expression of the surface markers.
MSCs used in our study were in passage 3 to avoid the
risk of morphological or functional changes that might
occur at long-term culture [10].
Intra-articular injections were performed using autolo-
gous and allogeneic pools of BM-MSCs. Allogeneic MSC
therapy is an interesting strategy using “off-the-shelf”
product. Allogeneic therapy avoid autologous limitations
such as the scarcity of MSCs, especially in cases where
MSC are low and the quality might be compromised as
it happens in aged individuals and disease, and also in
situations where autologous MSCs might have the same
genetic defects as the patient [9, 32]. In addition, allo-
geneic use of MSCs offers the possibility of selecting the
most suitable donors according to their proliferation
rate, their differentiation ability or their immunoregula-
tory properties.
The allogeneic BM-MSC pool offers the advantage of
availability of elevated number of MSCs for the treat-
ment of acute orthopedic lesions without the inherent
period (4–6 weeks) associated with isolation and expan-
sion of autologous MSCs [26]. Furthermore, the prolifer-
ation rate and chondrogenic differentiation capacity of
MSCs might be different because of individual-related
factors [11] and also their immunomodulatory proper-
ties, so the use of several donors could attenuate this
variability. The results of this study show that intra-
articular inoculation of equine BM-MSC, independently
of their origin (autologous or allogeneic pool), or the
number of doses, produces a transitory inflammatory re-
action that becomes restored to normal values 10 days
later, without any anti-inflammatory or analgesic drug
administration. This temporary inflammation was de-
tected in both clinical and synovial (TP, WBC and NC)
parameters. Our results are similar to other clinical evi-
dence recently described after injection of autologous
and allogeneic MSCs in equine healthy joints [10, 11].
Similarly, reports using an equine synovitis model have
showed that allogeneic MSCs induce an initial mild self-
limiting inflammatory reaction when administered
within the inflamed joint, but MSCs reduced the syn-
ovial fluid cell populations in this model [28]. Slight
lameness was noted only in one animal 24 h post autolo-
gous MSC administration (Injection 1). This animal also
showed more marked signs of synovitis at this time.
Allogeneic MSCs injection did not lead to any grade of
lameness in any horse at any time. Mild to severe lame-
ness 24 h post injection of allogeneic CB-MSCs in in-
flamed joints has been reported, but lameness did not
correlate with synovitis induced by MSCs injection [28].
We assessed the articular inflammatory response after
a second inoculation of the allogeneic equine MSC
(Injection 3). No hypersensitivity response was observed.
The re-injection caused a transient inflammatory reac-
tion similar to that detected after Injections 1 and 2.
Synovial parameters (TP, WBC and NC) changes were
more evident than clinical signs, but spontaneously
returned to baseline by 10 days in all cases.
Although the cause of inflammation produced by the
injection of BM-MSCs is still unknown [26], there are
different factors that might be taken into account. The
production, expansion and infiltration procedures were
carried out in aseptic conditions, leaving out a possible
septic origin that was supported by no detection of clin-
ical or cytological evidence of a possible septic arthritis.
Besides the inflammation was self-limiting and resolved
without any medication, which is incompatible with the
development of iatrogenic joint sepsis [33]. There is con-
troversy about the cause of this joint inflammation.
Some authors point out that any articular injection may
cause at least a slight synovitis, or even a kind of reactive
synovitis could occur after joint injection of any type of
product [33–35]. Other authors suggest that the inflam-
matory response that follows administration of MSCs
may be due to the exquisite sensitivity of healthy equine
joints to the introduction of pro-inflammatory cytokines
that may be present in cell culture, or even to chemical
or biologically active substances present in the culture
medium used, such as fetal bovine serum [26]. Recently,
it has been demonstrated that equine allogeneic MSCs
are capable of eliciting antibody responses in vivo, which
might be cross-reactive with donor MHC types different
to the recipient [36]. In our experimental conditions,
our results suggest that the significant increase in syn-
ovial parameters detected during the first few days after
LRS injection could be an inflammatory effect of re-
peated arthrocentesis. Similar results were found by
Jacobsen et.al. [37] and Sanchez Teran et.al. [38].
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Differential inflammatory responsiveness of the joints
have also been discussed [11]. Indeed, the distal inter-
phalangeal joint and tarso-crural joint are more suscep-
tible to reactive arthritis following intra-articular
injection [37]. In this context, differences in the inflam-
matory response between autologous BM-MSCs and
the allogeneic pool of BM-MSC treated joints could
be due to inter-individual and inter-joint variability.
Certainly, the autologous injection was made in the
tarso-crural joint and allogeneic doses were adminis-
tered in the radio-carpal joint, which seems to be less
prone to inflammatory reaction than the tarso-crural
joint [34].
In agreement with other similar trials, our results
showed higher WBC and NC increases than those ob-
served for protein values [10, 26]. This difference may
be due to the kinetics of these two inflammation
markers [26, 39]. This trend has also been observed in
other works analyzing the response of equine synovial
fluid to intra-articular injection of different inflammatory
stimuli [40].
Conclusion
Our experiments have shown a transitory inflammatory
response in all injected equine healthy joints to the ad-
ministration of autologous, and single and repeat doses
of allogeneic MSCs pooled from several donors. This
situation resolved spontaneously within 10 days post-
inoculation. The different conditions in healthy and in-
flamed joints do not allow to directly extrapolating our
results to an articular damage situation. Despite this, we
suggest based on these findings that repeat intra-
articular administration of an allogeneic pool of BM-
MSCs could be used as a safe strategy, enhancing the
MSCs availability. The absence of a hypersensitivity re-
sponse to the second allogeneic BM-MSCs injection
could also be considered an important contribution to
the in vivo transplantation of MSCs, since several injec-
tions could potentiate the therapeutic benefit of these
cells. These results could notably contribute to the de-
velopment of stem cell based therapies for equine and
human joint diseases.
Methods
Animals
Six crossbreed saddle gelding horses aged from 3 to
7 years were used in this study. Absence of musculoskel-
etal abnormalities in the tarso-crural and radio-carpal
joints was determined by clinical and radiological exam-
ination, including absence of lameness, palpation, range
of motion, static and dynamic flexion tolerance and ab-
sence of radiological abnormalities.
All procedures were carried out under Project Licence
(PI 09/12) approved by the in-house Ethic Committee for
Animal Experiments from the University of Zaragoza. The
care and use of animals were performed in accordance with
the Spanish Policy for Animal Protection RD53/2013,
which meets the European Union Directive 2010/63 on the
protection of animals used for experimental and other
scientific purposes.
Study design
Three batches of injections (Injections 1, 2 and 3) were
performed in all horses by a single blinded researcher
(Nekane Ardanaz: NA). Joint treatments were randomly
assigned. The same researcher also carried out the as-
sessment of the clinical and inflammatory response on
days 0, 1, 2, 3, 5 and 10 after each intra-articular admin-
istration of the tree Injections. Horses were not ban-
daged or medicated with any anti-inflammatory,
antibiotic or analgesic drugs in order to not interfere
with the inflammatory response, and to provide an un-
altered clinical response to the MSC injections through-
out the experiment.
Injection 1: All horses were blindly injected in the
tarso-crural joints. One of the joints was inoculated
with 3 mL of Lactated Ringer’s solution (LRS), which
was used as control vehicle. The contralateral joint was
treated with 25x106 autologous BM-MSCs suspended
in 3 mL of LRS.
Injection 2: Ten days after the Injection 1 each horse
was blindly inoculated in their radio-carpal joints. One
of the joints was injected with 3 mL of LRS (control)
and the contralateral was inoculated with a pool of
25x106 allogeneic BM-MSCs (5x106 BM-MSCs from
each donor) diluted in 3 mL of LRS. For each individual
horse, the BM-MSC pool used was derived from all
other animals in the study but excluded BM-MSCs
from the animal in question.
Injection 3: The same procedure described for
Injection 2 was replicated 10 days later, once the
inflammatory parameters after Injection 2 returned to
normality.
MSC isolation, culture, expansion, cryopreservation,
differentiation and characterization
Horses were sedated with romifidine (0.04 mg/kg
IV) and butorphanol (0.02 mg/kg IV) and were
placed in a restrain stock. Approximately 60 mL of
bone marrow (BM) aspirate from the 5th sternebrae
from each horse were aseptically collected in heparinized
syringes [41]. Bone marrow derived mesenchymal stem
cells (BM-MSCs) were obtained from the BM aspirates.
BM aspirates were diluted 1:3 with PBS and then lay-
ered over Lymphoprep (Atom) and centrifuged for
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20 min at 1700 g. The mononucleated cell population
layer above the Lymphoprep was aspirated and washed
twice with PBS (Gibco). The pellet was resuspended in
10 mL growth medium, consisting of low glucose
Dulbecco Modified Eagle’s Medium (DMEM) and sup-
plemented with 10 % fetal bovine serum, 1 % glutamine
and 1 % streptomycin/penicillin (all from Sigma-
Aldrich). Cells were counted, plated at a density of 2 ×
106 nucleated cells/cm2 in 6-well plates and incubated at
37 °C, 5 % CO2. Cells were washed twice with PBS after
24, 48 and 72 h of incubation and were maintained in
growth medium until reaching approximately 80 % con-
fluence. The cells were then detached by treating with
0.25 % trypsin-EDTA (Sigma Aldrich), counted in a
Neubauer counting chamber using trypan blue staining,
and plated in T75 or T175 flasks (Becton Dickinson) at
5000 cells/cm2. The cells were trypsinised repeatedly
until the third passage and then were cryopreserved in
106 aliquots with freezing medium consisting on 90 %
FBS and 10 % DMSO. Approximately 106 cells from
passage three were thawed at 37 °C and plated in a
T75 flask for three days to re-adjust the culture con-
ditions prior to being characterized and used on the
different Injections.
Cells were characterized as BM-MSCs by tri-lineage
differentiation and gene expression profile of cell surface
markers. The tri-lineage differentiation ability was
assessed plating cells at 20.000 cells/cm2 or 2.500 cells/
cm2 in 12-well plates and cultured for 7 or 14 days in
osteogenic or adipogenic medium, respectively. For
chondrogenic differentiation, approximately 500.000
cells were pelleted in 15 mL conical tubes and cultured
in chondrogenic medium for 21 days. Differentiation
ability was evaluated for each lineage by specific staining,
using Alizarin Red S (Sigma-Aldrich), Oil Red O and
Alcian Blue for osteogenic, adipogenic and chondrogenic
differentiation, respectively. Methodology and compos-
ition of differentiation media were described by Ranera
et al [31].
Phenotype of the BM-MSCs was determined by Real
Time quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated from approximately 106 cells
using the RNA spin mini (GE Healthcare Lifesciences,
LittleChalfont, UK) and DNAse turbo (Ambion, Foster
City, California, USA.) kits. Afterwards, reverse tran-
scription of 1 μg of total RNA to complementary DNA
was performed using the Superscript kit (Invitrogen,
Carlsbad, CA, USA). All kits were used according with
the manufacturer’s instructions. The expression levels of
genes coding for MSC surface markers (CD90, CD105,
CD73 and CD166), haematopoietic markers (CD34 and
CD45) and immunogenic molecules (MHC-I and MHC-
II) were analyzed using a StepOne Real Time PCR Sys-
tem device (Applied Biosystems) as described by Ranera
et al. [31, 42]. All reactions were carried out in triplicate
in a total volume of 10 μl with 2 μl of cDNA as template
and Fast SYBR Green Master Mix (Applied Biosystems).
The amplification consisted of 40 cycles of 3 s at 95 °C
and 30 s at 60 °C. For analyzing and presenting the gene
expression data, a relative expression method was used:
the comparative Ct method was used to give the levels
of gene expression. Expression level of every gene in
each sample was normalized through a normalization
factor (NF), calculated as the geometric mean of the
quantity of 2 housekeeping genes, GAPDH and B2M
[43]. The data of the gene of interest is presented as
mRNA expression level relative to housekeeping genes,
using the cycle threshold (Ct) values to calculate the
expression.
Primer Express 2.0 software was used to design
primers based on known equine sequences. Information
about primers is shown in Additional file 4.
Proliferation rates, i.e. cell doubling times (DT), was
calculated before freezing and after thawing using the
formulae CD = ln (Nf/Ni)/ln2 and DT = CT/CD, where
Nf indicates final number of cells; Ni indicates initial
number of cells, CT indicates culture time and CD indi-
cates cell doubling number.
For the experimental treatments, MSCs were detached
from flasks by treating with 0.25 % trypsin-EDTA. MSCs
were then rinsed three times with PBS and subsequently,
three times with Lactated Ringer’s Solution in order to
remove any residuary FBS.
Clinical determinations
Evidence of synovial effusion and joint distention were visu-
ally assessed. One of the classical signs of inflammation is
heat, which is exchanged between injured tissues and the
environment [44]. Heat was quantified by measuring the
skin temperature at each time point by non-contact infra-
red laser thermometer (GIM 530 MS Intelligent Multi
Purpose Infrared Thermometer, Thermolab). Static and dy-
namic lameness examinations were performed following
the parameters established by the American Association of
Equine Practitioners (AAEP) [45]. Ultrasonography mea-
surements were carried out in triplicate, using the same
anatomical references. The evaluations of the articular sur-
face, the thickness between skin and articular surface and
the relaxation of the synovial recesses were performed
using an Ultrasound machine (HDI-3500, ATL) and a
10 MHz linear transducer. All the parameters in the clinical
assessment were evaluated by a researcher blinded to the
Injections administered.
Assessment of synovial fluids
Synovial fluid (2 mL) samples from each control and
treated joints were taken at the predefined time points.
Total protein values (TP) were measured by refractometry
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[46] using a RHB-32 Hand-held brix refractometer
(Spectrum Technologies). White blood cells (WBC/μL)
and neutrophil (NC/μL) countings were carried out using
the Neubauer chamber. Joints with synovial values of TP
<2 g/dL, WBC <1500 cells/μL and NC 250 neutrophil/μL
were considered as healthy [47]. All the parameters
assessed in the synovial fluid were evaluated by a re-
searcher blinded to the Injections administered.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0.
Differences between control and treated joints at each
time point were analyzed by Student’s t test. Significance
level was set at P < 0.05 for all analyses.
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